Sertoli cells as biochambers by Sanberg, Paul R. et al.
I Il11 l111111 Ill Il11 Il11 US006790441Bl III Il11 11111 Il1 11111 11ll ll Il1 1111 Il  
(12) United States Patent 
Cameron et al. 
(io) Patent No.: 
(45) Date of Patent: 
US 6,790,441 B1 
Sep. 14,2004 
(54) SERTOLI CELLS AS BIOCHAMBERS 
(75) Inventors: Don F. Cameron, Lutz, FL (US); Paul 
R. Sanberg, Spring Hill, FL (US); 
Samuel Saporta, Tampa, FL (US); 
Joelle J. Hushen, Lithia, FL (US) 
(73) Assignee: University of South Florida, Tampa, 
FL (US) 
Subject to any disclaimer, the term of this 
patent is extended or adjusted under 35 
U.S.C. 154(b) by 0 days. 
( * ) Notice: 
(21) Appl. No.: 09/593,629 
(22) Filed: Jun. 13, 2000 
(51) Int. C1.7 .......................... AOlN 65/00; C12N 5102; 
C12N 5106; C12N 5100 
(52) U.S. C1. ...................... 424/93.1; 4351325; 4351347; 
4351373; 4351382; 4351383 
(58) Field of Search ............................... 424193.1, 93.7, 
4241559; 4351325, 347, 373, 382, 383 
(56) References Cited 
U.S. PATENT DOCUMENTS 
5,702,700 A 1211997 Sanberg et al. 
5,725,854 A 311998 Selawry 
5,759,534 A 611998 Selawry 
5,827,736 A 1011998 Heller et al. 
5,830,460 A 1111998 Sanberg et al. 
5,843,430 A * 1211998 Selawry ..................... 424193.7 
5,849,285 A 1211998 Selawry 
5,942,437 A * 811999 Sanberg et al. ............. 4351374 
5,958,404 A 911999 Selawry 
6,001,643 A * 1211999 Spaulding ................ 4351298.2 
6,036,951 A 312000 Sanberg et al. 
6,037,175 A 312000 Cameron et al. 
FOREIGN PATENT DOCUMENTS 
WO WO 96128174 A1 911996 
WO WO 96133264 A1 1011996 
WO WO 97133470 A1 911997 
WO WO 01166698 A1 912001 
OTHER PUBLICATIONS 
Moira A. L. Maley et al. Extracellular Matrix. Growth 
Factors. Genetics Their influence on Cell Proliferation and 
Myotube Formation in Primary Cultures of Adult Mouse 
Skeletal Muscle. Experimental Cell Research. 219. pp 
Willing et a1 Sertoli cell transplants their use in the treatment 
of neurodegenrative disease Nov. 1998 pp 474477.* 
Korbutt Testicular Sertoli cells exert both protective and 
destructive effects on syngeneic islet grafts in non-obese 
diabetic mice 2000 pp 474-480.* 
Korbutt et al, Diabetologia 2000 Apr;43:474-80.* 
Hadley et al, J Cell Biol 1985;101:1511-22.* 
Van der Wee et al, Exp. Cell Res 1999;252:175-85.* 
Hadley et al. J Cell Biol 1985:101:1511-22.* 
van der Wee et al. Exp Cell Res 1999:252:175-85.* 
169-179 ATCC. pp. 1-7.* 
Byers S et a1 “Sertoli Cell Junctions and the Seminiferous 
Epithelium Barrier”, pp 431446, in The Sertoli Cell, L D 
Russell and M.D. Griswold. Eds. Cache River Press, 1993. 
Cameron, D F et a1 “Longterm Microgravity Coculture of 
Sertoli Cells and Islets Enhances Insulin Secretion”Endo- 
crin. Proc., Jun. 15, 1999. P2-230, abstract. 
Cameron, D.F. et a1 “Formation of Sertoli Cell-Enriched 
Tissue Constructs Utilizing Simulated Microgravity Tech- 
nology” Annals New York Acad. Sci., Nov. 2001. 944. 
Cameron, D F et a1 “Formation of Insulin-Secreting, Ser- 
toli-Enriched Tissue Constructs by Microgravity Coculture 
of Isolated Pig Islets and Rat Sertoli Cells” In Vltro Cell Dev 
Bio1.-Animal, Sep. 2001, 37. 490-498. 
Clermont, Y., “Introduction to the Sertoli Cell”, pp. 
XXI-XXV, in The Sertoli Cell. L D Russell and M D 
Griswold Eds. Cache River Press, 1993. 
De Cesaris P et a1 “Immunosuppressive Molecules Produced 
by Sertoli Cells Cultured in vitro Biological Effects on 
Lymphocytes” Biochemical and Biophysical Res Comm. 
Aug. 14, 1992, 186(3): 1639-1646. 
Djakiew, D and M. Onoda Multichamber Cell Culture and 
Directional Secretion pp 181-194, in The Sertoli Cell L D 
Russell and M D Griswold. Eds. Cache River Press, 1993. 
Free M J et a1 Respiratory Gas Tensions in Tissues and 
Fluids of the Male Rat Reproductive Tract Biology of 
Reproduction, 1976 14: 481488. 
Whitmore, W F et a1 “The Role of Germinal Epithelium and 
Spermatogenesis in the Privileged Survival of Intratesticular 
Grafts” The J .  Urology, Oct. 1985, 134 782-786. 
Wyatt, C R et a1 “Suppression of lymphocyte proliferation 
by proteins secreted by cultured Sertoli cells” J Reproduc- 
tive Immunology 1988 14 27-40. 
Alderson, D. et a1 (1987). The Isolation of Purified Human 
Islets of Langerhans. Transplant Proc. 19:916-917. 
Alison E. et a1 (1998). Sertoli cell transplants: their use in the 
treatment of neurodegenerative disease. Mol. Med. Today, 
Bardin, C.W, et a1 (1988). The Sertoli Cell. In: The Physi- 
ology of Reproduction. Knobil, E. and J. Neil (eds). Raven 
Press, Ltd., New York. Pp 933-974. 
420-428. 
4: 471-477. 
(List continued on next page.) 
Primary E x a m i n e r h n e  M. Wehbe 
Assistant Examiner-. Janice Li 
(74) Attorney, Agent, or FirmSaliwanchik, Lloyd & 
Saliwanchik 
(57) ABSTRACT 
According to the present invention, there is provided a 
biological chamber system having a biochamber defined by 
outer walls of Sertoli cells. Also provided is a transplantation 
facilitator including a biochamber. A method of making 
biochambers by co-culturing facilitator cells and therapeutic 
cells and then aggregating the facilitator celes is also pro- 
vided. Also provided is a method of transplanting cells by 
incorporating transplant cells into a biochamber and trans- 
planting the biochamber containing the transplant cells. 
25 Claims, 6 Drawing Sheets 
https://ntrs.nasa.gov/search.jsp?R=20080005166 2019-08-30T03:03:30+00:00Z
US 6,790,441 B1 
Page 2 
OTHER PUBLICATIONS 
Barker, C.F. et a1 (1968). The Role ofmerent  Lymphocytes 
in the Rejection of Skin Homografts. J .  Exp. Med. 
Becker, J.L. et a1 (1993). Three-Dimensional Growth and 
Differentiation of Ovarian Tumor Cell Line in High Aspect 
Rotating-Wal Vessel: Morphologic and Embryologic Con- 
siderations. J .  Cellul. Biochem, 51:283-289. 
Bellgrau, D., et a1 (1995), A role for CD95 Ligand in 
Preventing Graft Rejection. Nature, 377:63&632. 
Borlongan, C.V. et a1 (1996). Functional recovery in female 
hemiparkinsonian rats following transplantation of Sertoli 
cells. Proc. Am. SOC. Nuer. Transp. 
Borlongan, C.V. et a1 (1997). Intracerebral transplantation of 
testis-derived Sertoli cells in female rats with 6 hydroxy- 
dopmine induced hemiparkinsonian promotes functional 
recovery. Exp. Neurol. 148:388-392. 
Born, W. and H. Wekerle (1982). Leydig Cells Nonspecifi- 
cally Suppress Lymphoproliferation in Vitro: Implications 
for the Testis as an Immunologically Privileged Site, Am. J .  
Reprod, Zmmunol. 2: 29 1-295. 
Born, W. et a1 (1981). Selective, Immunologically Nonspe- 
cific Adherence of Lymphoid Cells and Myeloid Cells to 
Leydig Cells. Eur: J .  Cell Biol. 25:76-81. 
Calafiore, R. et a1 (1990). A Method for the Massive 
Separation of Highly Purified, Adult Procine Islets of 
Langerhans. Metabolism. 39: 175-181. 
Cameron,D.F. et a1 (1990). Successful IsletiAbdominal Tes- 
tis Transplantation Does Not Require Leydig Cells, Trans- 
plantation. 50:649-653. 
Cameron, D.F. et a1 (1990). Sustained Hyperglycemia 
Results in Testicular Dysfunction and Reduced Fertility 
Potential in BBWOR Diabetic Rats. J.  Physiol., 259 (Endo- 
crinol. Metab., 22); E881-E889. 
Cameron, D.F. et a1 (1991). Hormonal Regulation of Sper- 
matid Binding to Sertoli cells In Vitro, J .  Cell. Sci., 
Cameron, D,F. et a1 (1993). Testosterone Stimulates Sper- 
matid Binding to Competent Sertoli cells In Vitro, Endo- 
crinol. J .  1:61-65. 
Cameron, D.F. et a1 (1996). Enhanced post-thaw viability of 
cryopreserved rat fetal brain cells by Sertoli cells by Sertoli 
cell Secretory products. Proc. Am. SOC. Neural. Transpl. 
Cameron, D.F. et a1 (1997). Post-thaw viability and func- 
tionality cryopreserved rat fetal brain cells co-cultured with 
Sertoli cells. Cell Transplant, 6: 185-189. 
Cameron, D.F. et a1 (1998). Development of Sertoli cell 
binding competence in the peripubertal rat, J. Andrology, 
Cantrell, D.A. et a1 (1984). The Interleukin-2 T-cell sys- 
tem: A New Cell Growth Model. Science, 224:1312-1316. 
Chervonsky, A.V. et a1 (1997). The role of Fas in autoim- 
mune diabetes. Cell, 89:17. 
DeCesarts, A. et a1 (1992), Inhibition of Lymphocyte Acti- 
vation by Sertoli Cell Immunosuppressive Factor(s), Zmmu- 
nologia et Zmmunofarmacologia, 12(2):86. 
Edgington, S.M. (1992), New Horizons for Stem-Cell 
Bioreactors, BioiTechnology 10:1099-1106. 
Evans M.G. et a1 (1990). Reversal of Diabetes in Dogs by 
Transplantation of Pure cryopreserved Islets. Transplanta- 
tion. 50:202-206. 
1281197-221. 
100: 623-633. 
19 1573-579. 
Fawcett, D.W. et a1 (1973). Comparative Observation on 
Intertubular Lymphatics and the Organization of the Inter- 
stitial Tissue of the Mammalian Testis. Biol. Reprod. 
Gainer, A.L. et a1 (1998). Improved survival of biolistically 
transfected mouse islet allografts expressing CTLA4-Ig or 
soluble Fas ligand. Transplantation. 66:194-9. 
Gondos, B. et a1 (1993). Postnatal and Pubertal Develop- 
ment. In: The Sertoli Cell, 1993, Russell LD, Griswold MD 
(eds). Cache River Press, Clearwater, Florida, pp 493-508. 
Goodwin, T.J. et a1 (1992). Morphologic Differentiation of 
Colon Carcinoma Cell Lines HT-29 and HT-29KM in 
Rotating Wall Vessels, Zn Vltro Cell. Dev. Biol. 28A47-60. 
Goodwin, T.J. et a1 (1993). Reduced Shear Stress: A Major 
Component in the Ability of Mammalian Tissues to Form 
Three-Dimensional Assemblies in Stimulated Microgravity. 
J .  Cellul. Biochem. 51:301-311. 
Goodwin, T.J. et a1 (1993). Rotating-Wall Vessel Coculture 
of Small Intestine as a Prelude to Tissue Modeling: Aspects 
of Stimulated Microgravity. Proceed Experiment. Biol. Med. 
Gray, D.W.R. et a1 (1984). A Method for the Isolation of 
Islets of Langerhans from the Human Pancreas. Diabetes. 
Green, C.J. et a1 (1978). Extensive Prolongation of Rabbit 
Kidney Allograft Survival after Short-Term 
Cyclosporin-A Treatment. Lancet. 1:182-1183. 
Griswold MD. Actions of FSH on mammalian Sertoli cells. 
In: The Sertoli Cell, 1993. Russell LD, Griswold MD (eds). 
Cache River Press, Clearwater, Florida, pp 493-508. 
Hadley, M. et a1 (1985). Extracellular matrix regulates 
Sertoli cell differentiation, testis cord formation and germ 
cell development in vitro. J .  Cell Biol. 101:1511-22. 
Head, J. et a1 (1983). Immune Privilege in the Testis. I. Basic 
Parameters of Allograft Survival. Transplantation, 
Head, J., et a1 (1983), Reconsideration of the Lymphatic 
Drainage of the Rat Testis. Transplantation: 35:91-95. 
Hedger, M.P. (1989), The Testis as an “Immunologically 
Suppressed” Tissue? Reprod. Fertil. Dev. 1:75-81. 
Hess, A.D. (1985), Effect of Interleukin 2 on the Immuno- 
suppressive Action of Cyclosporine. Transplantation, 
Homan, W.P. et al. (1980), Studies on the Immunosuppres- 
sive Properties of cyclosporin A in Rats Receiving renal 
Allografts . Transplantation, 29 : 3 6 1-3 66. 
Horaguchi,A. and R.C. Merrell(1981), Preparation of Vible 
Islet Cells from Dogs by a New Method. Diabetes., 
Kang, S-M. et a1 (1997), Fas ligand expression in islets of 
Langerhans does not confer immune privilege and instead 
targets them for rapid destruction. Nature Med. 3:738. 
Kaufman, D.B. et a1 (1990), Functional Outcome as Influ- 
enced by Islet Number and Implantation Site. Transplanta- 
tion, 50:385-391. 
Kneteman, N.M. et a1 (1986), Isolation and Cryopreserva- 
tion of Human Pancreatic Islets. Transplant. Proc. 
Kneteman, N.M. et a1 (1990). Prolonged Function of Canine 
Fragments Autotransplanted to the Spleen by Venous 
Reflux. Transplantation, 49: 679-68 1. 
Kuhn F., et a1 (1985), Morphological Investigations in 
Human Islets of Langerhans Isolated by the Velcro Tech- 
nique, Biomed. Biochem. Acta. 44:149-153. 
91500-512. 
2021181-192. 
33: 1055-1061. 
36: 423-43 1. 
39: 62-68. 
30: 455-458. 
181182-185. 
US 6,790,441 B1 
Page 3 
Lau, H, et a1 (1996), Prevention of islet allograft rejection 
with engineered myoblasts expressing FasL in mice. Sci- 
ence, 273:109. 
Leapman, S.B., et a1 (1981), Differential Effects of 
Cyclosporine A on Lymphocyte Subpopulations. Transplant 
London, N.J.M. et a1 (1990), A Simple Method for the 
Release of Islets by Controlled Digestion of the Human 
Pancreas. Transplantation 49: 1109-1113. 
Martin, D.C. (1982), Malignancy in the Cryptorchid Testis. 
Urol. Clinics N. Amer. 9:371-376. 
Muruve, D. et a1 (1997). Adenoviru-mediated expression 
of Fas ligand indices hepatic apoptosis after systemic admin- 
istration and apoptosis of ex vivo-infected pancreatic islet 
allografts and isografts. Human Gene Ther. 8:955. 
Naji, A. et a1 (1981), Prevention of Diabetes in Rats by Bone 
Marrow Transplantation. Ann. Surg. 194:328-338. 
Ogasawara, J. et a1 (1993), Lethal effect of the anti-Fas 
antibody in mice. Nature, 364306. 
Othberg, A.I. et a1 (1998), Preparation of cell suspension for 
co-transplantation: methodological considerations, Neuro- 
sci let., 247:lll-114. 
Othberg, A.I. et a1 (1998). Trophic effect of porcine Sertoli 
cells on rat and human ventral mesencephalic cells and hNT 
neurons in vitro. Cell Transplant., 7:157-164. 
Prowse, S J. et a1 (1986), Islet Allografts are Destroyed by 
Disease Occurence in the Spontaneously Diabetic BB Rat, 
Diabetes, 35:11&118. 
Ricordi, C. et a1 (1989), Automated Islet Isolation from 
Human Pancreas. Diabetes. 38 (Suppl. 1):14&142. 
Ricordi, C., et a1 (1990). Isolation of the Ilusive Pig Islet, 
Surgery, 107:688-694. 
Sanberg, P.R. et a1 (1966), New horizons in xenograft 
cross-species transplantation for neurodenegerative disease. 
Proc. Internat. Behav. Neurosci. SOC. 
Sanberg, P.R. et a1 (1995), The effects of Sertoli cell 
co-transplantation with chromaffin cells in the rat model of 
Parkinson’s disease. Nature’s Letters (In review). 
Sanberg, P.R. et a1 (1996). Testis-derived Sertoli cells sur- 
vive and provide localized immunoprotection for xenografts 
in rat brain. Nature Biotechnol. 14:1692-5. 
Sanberg, P.R. et a1 (1996). Transplantation of testis-derived 
Sertoli cells into the Mammalian brain. Third Internat. Cong. 
Cell Transpl. SOC. 
Sanberg, P.R. et a1 (1997), Testis-derived cultured Sertoli 
cell as a natural FasL secreting cell for immunosuppressive 
cellular therapy, Cell Transplant., 191-193. 
Sanberg, P.R. et a1 (1997). TestisAerived Sertoli cells have 
a trophic effect on dopamine neurons and alleviate hemi- 
parkinsonian in rats. Nature Medicine, 3:1129-1132. 
Scharp, D.W. (1988), The Elusive Human Islet; Variables 
Involved in its Effective Recovery, In: VanSchilgaard R., 
Hardy M.A. eds, Transplantation of the Endocrine Pancreas 
in Diabetes Mellitus. Amsterdam Elsevier, p. 97. 
Scharp, D.W. et a1 (1987). Low Temperature Culture of 
Human Islets Isolated by the Distention Method and Purified 
with Ficoll or Percoll Gradients. Surgery. 102:869-879. 
Schwarz, R.P. et a1 (1992). Cell Culture for Three-Dimen- 
sional Modeling in Rotating-Wall Vessels: An Application 
of Stimulated Microgravity. J. Tiss. Cult. Meth. 14:51-58. 
Selawry, H. et a1 (1993). Sertoli Cell-Enriched Fractions in 
Successful Islet Cell Transplantation. Cell Transplantation 
PVOC. 131405-409. 
2: 123-129. 
Selawry, H. et a1 (1993), Sertoli Cell-Enriched Fractions in 
Successful Islet Cell Transplantation. Cell Transplantation, 
Selawry, H., et a1 (1986). Effect of Cyclosporine on Islet 
Xenograft Survival in the BB/W Rat. Transplantation. 
Selawry, H., et a1 (1987), Extended Survival of the MHC- 
Compatible Islet Isografts in the Spontaneously Diabetic 
BB/W Rat. Diabetes. 36:1061-1070. 
Selawry, H.., et al. Production of a Factor, or Factors, 
Suppressing 11-2 Production and T cell Proliferation by 
Sertoli Cell-Enriched preparations. Transplantation, 
Selawry, H.P. et a1 (1989). Abdominal Intratesticular 
Islet-Xenograft Survival in Rat, Diabetes. 38:220-223. 
Selawry, H.P. et a1 (1996). Sertoli Cell-induced Effects on 
Functional and Structural Characteristics of Isolated Neo- 
natal Porcine Islets. Cell Transplantation, 5:517-24. 
Selawry, H.R. et a1 (1985). Intratesticular Islet Allografts in 
the Spontaneously Diabetic BB/W Rat. Diabetes. 
Skinner, M.K. (1993). Secretion of Growth Factors and 
Other Regulatory Factors, In: The Sertoli Cell, 1993. Russell 
L.D, Griswold MD (eds). Cache River Press, Clearwater, 
Florida. pp 493-508. 
Tanaka, M. et a1 (1997), Lethal effect of recombinant human 
Fas ligand in mice protreated with Propionibacterium acnes. 
J.Zmmuno1. 158:2303. 
Thompson, S.C. et a1 (1990). Preparation and Assessment of 
Tissue for Transplantation and its In Vivo Development in 
Athymic (Nude Mice). Transplantation, 49:571-581. 
Warnock, G.L. et a1 (1988), Studies of the Isolation and 
Viability of Human Islets of Langerhans, Translantation, 
Warnock, G.L., et a1 (1989), Viable Purified Islets from 
Collagenase-Perfused Human Pancreas. Diabetes. 38 
(Suppl.1): 136-139. 
Weringer, E.J. et a1 (1985). Immune Attack on Pancreatic 
Islet Transplants in the Spontaneously Diabetci, Biobreed- 
ingmorcester (BB/W) Rat is not MHC Restricted. J. Zmmu- 
nol. 134:2383-2391. 
Whitmore, W.F. et a1 (1978), Intratesticular Grafts: The 
Testis as an Exceptionally Immunologically Privileged Site, 
Trans. Am. Assoc. Gen-Urinary Surg. 70:76-80. 
Wickelgren, L (1996), Muscling Transplants into Mice, 
Science. 273: 33. 
Williams, H.J.H., P. Barkham, and N.G.P. Slater (1978). 
Testicular Relapse in Acute Leukemia, Lancet. 
Willing, A.E. et a1 (1998). Sertoli transplants to treat neu- 
rodegenerative disease. Mol. Med. Today, 4:471-477. 
Willing, A,E. et a1 (1999). Sertoli cells decrease microglia 
response increase engraftment of human hNT neurons in the 
hemiparkinsonial rat straitum. Brain Res. Bul., 48:441-444. 
Willing, A.E. et a1 (1999). Sertoli cells enhance the survival 
of co-transplanted dopamine neurons. Brain Research, 
Yagita, H. et a1 (1996). CD95 ligand in graft rejection, 
Nature, 379-682. 
* cited by examiner 
2: 123-129. 
42: 568-575. 
521846-850. 
34: 1019-1023. 
451957-963. 
211152-1156. 
8221246-250. 
U S .  Patent Sep. 14,2004 
e 
0 
a 
L u 
.I 
c, 
2 
. . . .  
.- 
: * m . r n = .  . 
':m m ' m ' m .  
. . . . .  
- 
. . . .  . . . .  . . . . .  . . . . .  
R ~ D B .  
Sheet 1 of 6 
. . .  
. .  
. . .  
. . .  
. . . .  . . . .  
. .  . .  . . . .  . . . .  . . . .  . . . .  . . . . .  . . . .  . . . .  . . . .  
: - :  . .  .@\ : :  
. . . . . . .  - 
J 4
a4 
+d 
c, 2 /  
2 a 
r/) 
US 6,790,441 B1 
a 
c 
d 
0 
L 
Lt 
w 
U 
LL 
U S .  Patent Sep. 14,2004 Sheet 2 of 6 US 6,790,441 B1 
U S .  Patent Sep. 14,2004 Sheet 3 of 6 US 6,790,441 B1 
t 
U S .  Patent Sep. 14,2004 Sheet 4 of 6 
7 
US 6,790,441 B1 
d- 
6 
w 
L4 
U S .  Patent Sep. 14,2004 Sheet 5 of 6 US 6,790,441 B1 
E 
6 
rl 
H 
E..l z + u cn 
k 
U S .  Patent Sep. 14,2004 Sheet 6 of 6 
3 
US 6,790,441 B1 
m 
0 
P 
U 
LL 
I 
. 
i' . 
-I f w* 
! 
. l  
t :a 
. 
US 6,790,441 B1 
2 1 
SERTOLI CELLS AS BIOCHAMBERS 
GRANT INFORMATION 
Supported in part by NASA Grant NAG8-1381 
BACKGROUND OF THE INVENTION 
1. TECHNICAL FIELD 
The present inventions relates to methods of transplanting 
cells. More specifically, the present invention relates to 
methods of transplanting cells to create a localized immu- 
nosuppressive effect in the tissue receiving the transplanted 
cells. 
2. BACKGROUND ART 
The central nervous system (CNS) has poor regenerative 
capacity which is exemplified in a number of neurodegen- 
erative disorders. An example of such a disorder is Parkin- 
son’s disease. The prefened pharmacotherapy for Parkin- 
son’s disease is the. administration of L-dopa which slows 
the progression of this disease in some humans. However, 
the neuropathological damage and the consequent behav- 
ioral deficits is not reversed by this treatment protocol. 
Laboratory and clinical studies have shown that the 
transplantation of cells into the CNS is a potentially signifi- 
cant alternative therapeutic modality for neurodegenetative 
disorders such as Parkinson’s disease (Wictorin et al., 1990; 
Lindvall et al, 1990; Sanberg et al., 1994; Bjorlund and 
Stenevi, 1985; Freeman et al, 1994). In some cases, trans- 
planted neural tissue can survive and form connections with 
the CNS of the recipient (i.e. the host). When successfully 
accepted by the host, the transplanted tissue (i.e. the graft) 
has been shown to ameliorate the behavioral deficits asso- 
ciated with the disorder (Wictorin et al, 1990). The obliga- 
tory step for the success of this kind of treatment is the 
prevention of graft rejection (i.e. graft acceptance). 
Currently, fetal neural tissue is the primary graft source 
for neural transplantation (Lindvall et al., 1990; Bjorklund, 
1992; Isacson et al., 1986; Sanberg et, a1 1994). Other viabie 
graft sources inclcude adrenal chromaffin cells and various 
cell types that secrete nerve growth factors and trophic 
factors. The field of neural tissue transplantation as a pro- 
ductive treatment protocol for neurodegenerative disorders 
has received much attention resulting in its progression to 
clinical trials. Preliminary results and clinical observations 
are promising although the graft rejection phenomenon 
remains problematic. 
Transplantation is also a valuable therapy for other 
diseases, such as insulin dependent diabetes mellitus. Insulin 
dependent diabetes mellitus is a major health problem. 
Current forms of therapy are not efficient and do not 
necessarily lead to a prevention of diabetic complications 
such as renal failure or blindness. A desirable treatment 
alternative is to provide the diabetic with an endogenous 
source of insulin, transplanting either the whole pancreas or 
the endocrine component of the pancreas (i.e. islets of 
Langerhans) into the diabetic recipient. Although, whole 
pancreas transplantation is successfully achieved with at 
least 60% of the grafts still functioning after transplantation 
for one year, a major weakness of this approach is the need 
for continuous immunosuppfessicn with powerful and toxic 
immunosuppressant drugs. 
The transplantation of the isolated islets containing the 
insulin secreting p-cells has received much attention in both 
animal models of diabetes (1-7) and in humans (8-16). 
However, islet transplantation to a variety of organ sites has 
met with little success as a viable treatment for diabetes. For 
example, islet transplantation of major histocompatibility 
complex (MHC) In the BB/W rat with spontaneous diabetes 
mellitus of autoimmune etiology results in destroyed islets 
within a few days by a recurrence of the autoimmune disease 
s (17). Likewise, destruction of grafted cells in the diabeiic 
BB/W rat occurs in grafted islets of MHC-incompatibie 
donors (18, 19). In the course of finding a suitable organ or 
tissue site for islet transplantation, it was discovered that the 
relocated abdominal testis, in particular, provides an extraor- 
IO dinary safe environment for extended survival of islet grafts 
and some relief of the diabetic complications (2Ck22). 
The testis has long been considered to be an immuno- 
logically privileged site (23-26) although the precise 
mechanism(s) by which it protects (suppresses) graft rejec- 
1s tion has not been clearly defined. Isolated islets of MHC- 
compatible donors have been shown to survive for extended 
periods of time in the non-imminosuppressed BB/W rat if 
implanted in the rat’s testis which is then placed into the 
host’s abdominal cavity (2Ck22,27). Although the mainte- 
20 nance of functional islets allografts is significant, a more 
difficult task and far more potentially significant 
accomplishment, in terms of clinical applicability, is the 
induction of normoglycemia in diabetic animals by the 
implantation of cross-species islet xenografts. 
Selawry and co-workers demonstrated the feasibility of 
such a procedure by successfully implanting incubated ham- 
ster islets into the BB/W rat abdominal testes (22,27,28). As 
a result of the abdominal testis/islet implant, the diabetic 
animals in these studies became normoglycemic. Long-term 
30 survival of the islet xenografts did not require prolonged 
immunosuppression to prevent rejection and to maintain 
normal sugar levels. In all cases implant viability required 
the protective milieu of the abdominal testis. It now appears 
that the donor origin of these isolated islets does not seem to 
influence their long-term survival. Islet cells grafted against 
major histocompatibility barriers (21), islet xenografts (27) 
and islets of MHC-compatible donors grafted into the testes 
of the diabetic BB/W rats functioned indefinitely in the 
recipient rendering the once diabetic animal normoglyce- 
The major weakness of this type of islet transplantation 
protocol is associated with the use of such an unconven- 
tional organ site. One major concern is the possibility of 
4s malignant transformation of germ cells at the higher core 
body temperature (29). More importantly, it would not be 
possible to use this transplantation protocol for the treatment 
of female diabetics. 
Histological examination of grafted abdominal testes has 
50 shown that the islet implants are always found within the 
interstitial compartment of the gonad, which consists of the 
endocrine cells of Leydig, macrophages, blood vessels, 
testicular interstitial fluid and extracellular macromolecules 
(31). Any of the secretory products of these cells are 
5s potentially capable of inhibiting the immune response. For 
instance, Born and Wekerie (32, 33) showed that active 
suppression of immune responses occurred by Leydig cells 
in vitro. These investigators speculated that the Leydig cells 
might prevent lymphocyte proliferative responses by creat- 
60 ing an “immunologically neutral zone” around the seminif- 
erous tubules and thus decreasing the danger of T-cell 
infiltration in to the intratubular spaces. It was shown by 
Williams (34) that leukemic cells accumulate in the inter- 
stitial compartment where they are apparently protected 
The “zone of protection” theory of Born and Wekerle (32) 
is attractive but it is not likely that this major component of 
2s 
3s . 
40 mic. 
65 against destruction by the host’s immune defenses. 
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the testicular interstitium, i.e. Leydig cells, is responsible for mechanism similar to the action of cyclosporin A which also 
the synthesis of some protective (immunosuppressant) fac- suppressed the production of IL-2 (4144).  
tor. Treatment of rats with ethane dimethanesulphonate Although this hypothesis is appealing and with Some 
(EDS), which selectively destroys the Leydig cell research support of an indirect nature, it remains to be 
completely, including steroidogenesis and all other 5 clearly unravelled. Recently, an additional and even more 
functions, had no adverse effects on the survival of intrat- ppealing hypothesis has received consideration attention. 
esticular islet allografts (30). It is not probable that germ Beligrau et al. (45*) in a letter to Nature showed that testis 
cells were involvedeither, since these cells are readily grafts that expressed Fas (CD95) ligand (FasL) survived 
depleted in the abdominal testis. By eliminatin of these coils, indefinitely when transplanted under the kidney capsule, 
Cameron and Sewiary concluded that the Sertoli cell was the 10 whereas testis grafts from gid mice (FasL deficient) were 
most probable testicular cell type providing the testis with its rejected when transplanted at the same site (45). A reverse 
unique immunologically privileged environment and that transcriptase-polymerase chain reaction analysis demon- 
this cell was most likely responsible for the unexplained strated that Sertoli cells constitutively Pypress FasL mRNA. 
absence of islet rejection in abdominal testes (30). Based on Additionally, they showed that isolated Sertoli cells derived 
these findings, Selawry and Cameron (35) attempted to 1s from normal, but not the gid mice survived indefinitely when 
create a similar immunologically privileged site outside of transplanted under the kidney capsule. They concluded that 
the testis utilizing Serioli cells as an immunosuppressant the expression of functional FasL by Sertoli cells accounts 
agent. To this end, isolated Sertoli cells were transplanted for the immune-privilege nature of testis and suggested a 
with isolated islets under the kidney capsule in female 
diabetic rats (see FIG. 1). Results from this study showed 
this novel transplantation protocol resulted in normoglyce- 
mia and that long-term islet allograft survival was achieved 
in a traditionally immunologically hostile site. We con- 
cluded that the Sertoli cell, independent of the testicular 
milieu, secreted an immunosuppressant factor(s) which was 
neither androgenic nor inhibitory to ovulation since 6 of the 
7 mated recipients became pregnant, carried a pregnancy to 
term and nursed the pups successfully (35). 
mechanism by which Sertoli cells induce localized immune 
20 privilege to islets co-transplanted with Sertoli cells in an 
otherwise immune hostile site (i.e. subjacent the kidney 
capsule). They pointed out that FasL ligand-mediated immu- 
nosuppression would be expected to primarily target acti- 
vated effector T cells rather than the activation steps that 
2s produce them, a mechanism by which Cyclosporin A pro- 
duces immunosuppression. This would suggest that by tar- 
geting only activated T lymphocytes, grafted cell-associated 
FasL may provide a highly specific form of immunosup- 
For the long-term treatment of diabetes, it is clear that the pression for ameliorating T-cell-dependent graft rejection. 
presence of viable Sertoli cells is a prerequisite for long- 30 TO this end, Lau et al, (46) transfected muscles cells with the 
term islet graph Success and maintenance of long-term beta FasL gene and co-transplanted them with islets beneath the 
cell function. We do not yet clearly understand, however, the kidney capsule and achieved local immunoprotection for the 
mechanism(s) which yield this observation. The likely grafted islet, albeit for only 80 days. In a letter to Science, 
explanation is that the Sertoli cells secret an immunosup- D Green declared this a stunning advance and declared that 
pressant factor(s) which cooperates with exogenous immu- 35 “It’s almost the Holy Grail of immunosuppression to restrict 
nosuppressants such as cyclosporine A to prevent a complete the suppression to the environment of the graft” (47). 
immune response and subsequently tissue rejection (35). Selawry and Cameron (35) achieved the Same results with 
Sertoli cells are active secretory cell types synthesizing long-term imnmunoprotection of the grafted islets and long- 
many proteins. Some of which promote growth and others term maintenance of normoglycemia in the diabetic rat by 
which have immunosuppressive capabilities (36,55). Initial 40 co-transplanting the islets with the natural producer of FasL, 
studies to verify such a factor have been positive to date. The Sertoli cells. The salient features of terminally differentiated 
effects of Sertoli cell conditioned media on Con Sertoli cells that make them important and preferable as a 
A-stimulated spleen lymphocyte proliferation showed that transplantation facilitator are 1) they live for the life of the 
products secreted by Sertoli cells inhibit lymphocyte prolif- donor and may survive for the life of the recipient host 
eration in a dose-dependent manner. The synthesis was 4s (providing, thereby, long-term FAS-L induced local immu- 
temperature dependent, occurrinry predominantly at 37” C. noprotection for the transplanted tissue or cells), 2) they do 
and hormone dependent, requiring the presence of follicle not divide and 3) they are easily isolated. 
stimulating hormone (FSH) in the Sertoli cell culture (see Since Sertoli cells secrete many growth enhancing factors 
FIG. 2). We further examined the mechanism of inhibition of including insulin-like growth factor I (55), the presence of 
lymphocyte proliferation and showed that preconditioned SO Sertoli cells, in addition to their immunoprotective protec- 
Sertoli cell media inhibited the production of the lymphok- tive properties, may provide additional tropic and growth 
ine IL-2 in a dose-dependent manner (see FIG. 3A). Because support to the transplant. Recently, Selawry et al, (48) 
the addition of exogenous IL-2 was not able to reverse this showed that when cryopreserved pig Sertoli cells were 
inhibition (see FIG. 3B), it appears likely that the precon- thawed and immediately place in culture with Sertoli cells, 
ditioned media inhibited both IL-2 production and ss there was a significant enhancement of post-thaw survival 
T-lymphocyte responsiveness to IL-2 (38) in concurrence and insulin secretion when compared to thawed islets not 
with similar finding by DeCesarts et al. (39) It is widely co-cultured with Sertoli cells. They suggested that insulin- 
acknowledged that all proliferating T-cells express IL-2 like growth factor I may have provided growth factor 
receptors,. while resting cells do not, and that interaction of support to the cell membrane known to be damaged during 
IL-2 with its receptor is an absolute requirement for the 60 freezing. Recently Sanberg et a1 (49-51) demonstrated that 
clonal expansion of activated T-cells (40). Because the Sertoli cells can survive in the brain and, in fact, protect 
prevention of IL-2 receptor interaction completely inhibits bovine adrenal chromaffin cell xenografts from rejection 
T-cell proliferation, we propose that both clonal expansion when co-transplanted into the striatum of the Parkinson’s 
and viability of activated T-cells are suppressed by an disease rat model. Even more significant, Sertoli cells alone 
immunosuppressive factor secreted by the Sertoli cells (35). 65 transplanted into the PD rat result in the amelioration of 
In this fashion, the putative Sertoli cell derived immuno- motion dysfunction to the same degree as do chromaffin 
suppressant would appear to suppress the rejection by a cells indicating a type of successful growth factor therapy, as 
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yet unknown, provided for by the transplanted Sertoli cells 
(52). Similar to islet cells, Cameron et a1 (53) have shown 
enhanced if the are co-cultured with Sertoli cells 
again indicating the generalized ability of Sertoli cell secre- 
tory products to support the viability of isolated cells, For 
both islets and neurons, the growth and viability enhancing 
characteristics of Sertoli cells were evident only when the 
Sertoli cells were present as opposed to only media soluble 
factors found in expended pre-conditioned Sertoli cell 
media. 
ne extra-testicular utilization of Sertoli cells in facili- 
tated transplantation holds enormous potential based of the 
cell’s ability to provide for long-term localized immunosup- 
pression and generalized growth enhancement of the trans- 1~ 
planted cells and tissues. There is a distinct advantage to 
utilizing whole Sertoli cells rather than specific growth or 
immunosuppressant factors in that the Sertoli cell appears to 
continue expressing its desirable transplantation facilitation 
properties as long as the cell survives in the host, which may 2o wherein: 
be for the life of the recipient. Because Sertoli cells cease 
mitotic activity following differentiation (54) and do not 
appear to re-acquire it following transplantation, it may be 
possible to transplant a stable population of Sertoli cells 
which remains stable for the life of the host. It is not an 25 
testicular Sertoli cells as transplantation facilitators opens 
the window to new and potentially significant protoco~s for 
SUMMARY OF THE INVENTION 
that the post-thaw viability of fetal brain cells is significantly According to the present invention, there is provided a 
biological chamber including outer walls of Sertoli cells and 
an inner lumen. Also provided is a transplantation facilitator 
including a biochamber which is formed from an engineered 
Sertoli tissue construct. A method of making biochambers 
by co-culturing facilitator cells and therapeutic cells is also 
provided. Additionally, there is provided a method of trans- 
planting cells by incorporating therapeutic cells into a bio- 
chamber and transplanting the biochamber containing the 
therapeutic cells. Further, a method of treatment using these 
engineered biochambers is also included. 
DESCRIPTION OF THE DRAWINGS 
Other advantages of the present invention will be readily 
appreciated as the Same becomes better understood by 
reference to the following detailed description when con- 
sidered in connection with the accompanying drawings 
FIGS. 1 A  and 1B are diagrams showing the information 
of a biochamber on a substrate. As shown in FIG. lB,  apical 
secretion in a closed compartment creates a fluid-filled 
lumen by appreciating hydrostatic pressure; 
between the conventional culture and a microgravity 
co-culture. As shown in FIG. 2A apical secretion in a closed 
hydrostatic pressure. As shown in FIG. 2B, microgravity 
In general, systematic, immunosuppression is necessary if coculture results in the integration of therapeutic cells into 
successful transplantation is to be achieved in humans. 
Immunosuppression of the entire body (i e. systemic) can FIG. 3 is a mechanism showing the way the Sertoli cells 
eventually, in graft acceptance, It is acquired, effect immuno-suppression at the graft site. Positive FasL, 
however, by the individual at medical risk making 35 immunostatining identifies Sertoli cells and suggest a 
the immunosuppressant therapy itself more of a liability than mechanism by which they may effect immune suppression at 
a benefit in cases, F~~ a lack of a better immnosup- the graft site. The expression of Fasl, by Sertoli cells induces 
pressant treatment, systemic immunosuppressants, with aPoPtosis of the invading immune cells by binding to the 
Cyclosporine-A (CsA) as the treatment choice, have been upregulated Fas receptors on these activated T-lYmPhocYtes. 
used as adjunctive therapy in neural transplantation proto- 4o This results in the attrition of these immune cells at the graft 
cols (Sanberg et al., 1994; Freeman et al., 1994; Borlongan site thereby down-regulating the responses-this 
et al., 1995). Arguably, systemic CsA treatment may be by an already well-defined mechanism occurink? naturally in 
contraproductive to successful graft acceptance in the CNS the m m m d i a n  system; 
because of its systemic effect and because CsA itself has FIG. 4 is a photograph showing Sertoli cells (SC) and 
been shown to cause detrimental side effects and may in fact, 45 islets (arrows) in a Sertoli-islet tissue construct created in a 
be cytotoxic to neural tissues (Berden et al., 1985; deGroen conventional co-culture; B-cells are immunostained for 
et al., 1984). insulin; 
It would be useful to develop a mechanism that enhances FIG. 5 is a photograph of Sertoli cells (SC) and B-cells 
the productive cell transplantation techniques already uti- (arrows) in a Sertoli-islet tissue construct created in a 
lized for neurodegenerative disorders, such as Parkinson’s SO conventional co-culture, B-cells are immunostained for 
disease. This mechanism should improve these protocols in insulin; 
ways which more the neurodegen- FIG. 6 is a photograph of Sertoli-Neuron-Aggregate-Cells 
erative disease process, more actively promote the re&&- (SNACS for in vitro following co-culture of rat Sertoli cells 
lishment Of and NT2 neuros in simulated microgravity utilizing the High 
alleviate the functional disabilities associated with the neural 55 Aspect Rotation velocity (HARV) bioreactor and 1 week 
tissue dysfunction. Likewise, it would be useful to provide HARV co-culture); and 
trophic support for the transplanted cells. Further, it would FIGS. 7A and 7B is a photograph of immunocytochemical useful if this support lead to the reduction or elimination of staining of mouse FasL, and human nuclear matrix proteins systemic immunosuppression while maintaining the ability in Sertoli-Neuron Aggregated Cells (SNACS) following to immunosuppress locally (i.e. at the graft site) by an 60 HARV incubated co-cultures (1 week HARV co-culture). immunosuppressant which is biologically tolerated by the 
DETAILED DESCRIPTION OF THE host. Sertoli cells may provide this desired option since it is 
INVENTION clear from the diabetic studies, as summarized above, that 
co-transplantation with Sertoli cells will deliver local immu- 
nosuppression and promote, therefore, efficient graft accep- 65 
tance and functional restoration of the tissue-related dys- 
function. 
understatement to recognize that the utilization of extra- 2A and 2B are diagrams the differences 
transplantation Success and represents the beginning ‘‘Of a 
new era in transplantation” therapy (47). 
compartment creates a fluid-fi11ed lumen by appreciating 
30 
biochambers; 
tissue physiology and better 
Generally, the present invention provides a biological 
chamber system which is used for transplating cells. More 
specifically, the biochamber is formed of facilitator cells 
US 6,790,441 B1 
7 8 
such as, but not limited to, Sertoli cells which form a is segregation of the Sertoli cells away from the therapeutic 
chamber or vessel having an inner cavity or lumen contain- cells during the process of Sertoli cell epithelization leaving 
ing therein a population of cells different than the facilitator the therapeutic cells residing within the newly-formed lumi- 
cells. In the preferred embodiment, this population of cells nal spaces. The luminal space(s) islare created during this 
include therapeutic cells. s reorganization of the Sertoli cells and the formation of the 
B~ “Biochamber” or ‘‘vessey’, it is meant that a number Sertoli-Sertoli junctions. These junctions form an intraepi- 
of cells are engineered in such a manner as to form discrete thelia1 barrier similar to that observed in the testis and 
walls about a lumen or center chamber, M~~~ specifically, referred to as the blood-testis barrier. Apical polarization of 
the biochamber is formed by a structural modification of the Sertoli cell secretion is the likely mechanism by which the 
Sertoli cells, this new structure being similar to the original 10 lumen is formed (FIGS. 1-31 The reorganized Sertoli cells 
Sertoli cell structure prior to cell harvesting, It is during this illustrated in FIGS. 1-3 create an item which is referred to 
harvesting that the Sertoli cells are reorganized to form a as the Sertoli cell biOChamber. 
central lumen in which the therapeutic cells are housed The Sertoli cell portion of the biochamber acts as a 
within a newly formed micro-environment. This micro envi- facilitator or a bridge cell for the transfer of material into and 
ronment can contain therein therapeutic cells, which are 15 out of the lumen. 
used for transplantation. By “facilitator cell”, as used herein, Examples of such biochambers, include but are not lim- 
it is meant to include a cell which is able to provide localized ited to, Islet, filled Sertoli cell &chambers (SICAS) and 
immunosuppression or otherwise facilitate or make more NT2 cell-filled biochambers (SNACS) which exemplify 
effective the transplant. The facilitator cells provide bio- how therapeutic cell types can be incorporated into the 
protection for the therapeutic or transplanted cells. This Zo Settoli cell biochamber. SICAS secrete insulin in response to 
bio-protection includes, but is not limited to, protection from a glucose challenge (180 mg %) and also suppress activated 
a biological source such as an immune response, whether lymphocytic proliferation (16). Similarly, SNACs enhance 
cellular or humoral. In the preferred embodiment, the facili- the differentiation of NT2 cells to the dopaminergic pheno- 
tator cell is a Sertoli cell. Such cells, as described type (17-18) and likewise provide for immunoprotection of 
hereinbelow, are able to reorganize to form walls defining an z5 the neurons as judged by the expression of FasL on the 
inner lumen. The biologicallliving walls provide a physical Sertoli cells (see FIG. 3). SICAs and SNACs are therapeutic 
as well as an immunological barrier for the cells contained cell-filled Sertoli cell biochamber products created by this 
therein. The apical secretions of Sertoli cells contribute to tissue engineering protocol and are designed for the use in 
the unique trophic-bridge micro-environment of the luminal therapeutic transplantation treatments for serious diseases 
spaces in which therapeutic cells reside. such as diabetes and Parkinson’s disease 
The term “therapeutic cell” as used herein, is meant to Since Sertoli cells are terminally differentiated, and the 
include the cells to be transplanted. For example, these cells are mitotically inactive. They live for a long period of 
therapeutic cells can include, but are not limited to, the time, and potentially as long as any therapeutic cell type that 
following cells: dopaminergic cells, pancreatic islet cells, can be engineered into the Sertoli cell biochamber. If trans- 
bovine chromaffin cells and immortalized neuron-like NT2 35 planted in a Sertoli cell biochamber, therapeutic cells can be 
cells. The cells are therapeutic in that they can secrete protected against immune surveillance and subsequent 
hormones, factors, or the like that can have a therapeutic rejection in a micro-environment (provided for by Sertoli 
effect upon the host. They, like the Sertoli cell walls, are cell secreted growth and trophic factors) that also maintains 
biosensitive in that they can respond to factors in their and stimulates theirfunctional phenotypes on a lona-term 
environment. 40 basis. This has a significant impact on the successful trans- 
By modifying the harvested Sertoli cell by the methods of plantation treatment of many serious diseases and on the 
the instant invention that the cells reorganize into a tissue status of transplantation biology in general. 
structure similar to that observed in the testis. They become The above discussion provides a factual basis for the use 
a protective and nurturing barrier tissue, encapsulating the 45 of Sertoli cell biochambers. The methods used with and the 
therapeutic cells in a unique micro-environment. Because utility of the present invention can be shown by the follow- 
the engineered Sertoli tissue construct captures the thera- ing non-limiting examples and accompanying figures. 
EXAMPLES peutic cells in their new environment, this produces a 
dynamic support system for the therapeutic cells whereby General Methods 
the discreet units become efficient and viable within this General methods in molecular biology: Standard molecu- 
special structure. Each biochamber becomes a discreet trans- lar biology techniques in the art and not specifically 
plant unit, both nurtured and immunoprotected, by the described were generally followed as in Sambrook et al,, 
Molecular Cloning: A Laboratory Manual, Cold Spring surrounding engineered Sertoli tissue. 
In the Preferred embodiment, Sertoli cells are isolated Harbor Laboratory Press, New York (1989), and in Ausubel 
from a mammal, such as, but not limited to a Prepubertal rat ss et al., Current Protocols in Molecular Biology, John Wiley 
or pig testes and co-cultured with a therapeutic cell type in and Sons, Baltimore, Maryland (1989) and in Perbal,: A 
a culture environment that enhances tissue formation. This Practical Guide to Molecular Cloning, John Wiley & Sons, 
can be accomplished by co-culturing the different cell types New York (1988), and in Watson et al., Recombinant DNA, 
in simulated microgravity culture utilizing the H M V  biore- Scientific American Books, New York and in Birren et a1 
actor or other culture technologies. In a further embodiment, 60 ~ ~ ~ ~ ~ ~ ~ ~ ~ l ~ ~ i ~ :  A Laboratory ~~~ ~l series, vols, 
the co-culturing is performed without the microgravity envi- 1 4  Cold Spring Harbor Laboratory Press, New York (1998) 
ronment. and methodology as set forth in U.S. Pat. Nos. 4,666,828; 
The addition of a basement membrane-like extracellular 4,683,202; 4,801,531; 5,192,659 and 5,272,057 and incor- 
matrix to the incubation medium induces the epithelization porated herein by reference. Polymerase chain reaction 
and polarization of Sertoli cells, and subsequent formation 65 (PCR) was carried out generally as in PCR Protocols: A 
of Sertoli-Sertoli junctional complexes between adjacent Guide To Methods And Applications, Academic Press, San 
Sertoli cells, and the formation of a lumen or lumina. There Diego, Calif. (1990). In-situ (In-cell) PCR in combination 
30 
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with Flow Cytometry can be used for detection of cells exocrine tissue) prior to incubation in HARV's with or 
containing specific DNA and mRNA sequences (Testoni et without Sertoli cells. HARV co-cultures were incubated at 
al, 1996, Blood 87:3822.) 37" for 28 days in defined incubation medium consisting of 
General methods in immunology: Standard methods in DMEM; F-12 supplemented with ITS+Retinol, and 1% 
immunology known in the art and not specifically described s Matrigel. Every 48 hours, 4 ml of media was removed and 
are generally followed as in Stites et al.(eds), Basic and replaced wtit fresh media. The SICAs were exposed to a 
Clinical Immunology (8th Edition), Appleton & Lange, standard glucose challenge (180 mg % glucose) after which 
Norwalk, Conn. (1994) and Mishell and Shuigi (eds), samples were collected every ten minutes for an hour and 
Selected Methods in Cellular Immunology, W. H. Freeman subsequently assayed for insulin by radioimmunoassay. Cell 
and Co., New York (1980). i o  viability was determined by trypan blue exclusion, the 
Immunoassays presence of 0-cells was determined by differential staining 
In general, immunocytochemistry ELISAs are the pre- with dipherrylthiocarbazone and/or insulin immunostaining, 
ferred immunoassays employed to assess a specimen. These and Sertoli cells were determined by FAS-L immunostain- 
assays are well known to those skilled in the art. Both ing. 
polyclonal and monoclonal antibodies can be used in the 15 B~ the end of the incubation period, Sertoli cells and islets 
assays. Where appropriate other immunoassays, such as had formed sizable (3-10 mm diameter) tissue constructs, 
radioimrnunoassaYs (RIA) can be used as are known to with those formed in Matrigel mediums being larger. Cell 
those in the art. Available immunoassays are extensively viability was high (>go%) and O-cells were detected in both 
described in the patent and scientific literature. See, for SICA the three separate HARV incubations, the presence 
example, U S .  Pat. Nos. 3,791,932; 3,839,153; 3,850.752. 20 of Sertoli cells in SICA's enhanced the basal and total 
3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; amount of insulin secreted in response to the glucose chal- 
3,935.074; 3,984,533; 3,996,345; 4,034,074; 4,098376; lenge when compared to islet-only HARV monocultures. In 
428793219; 5,0112771 and 5,281,521 as well as Sambrook et the presence of Sertoli cells, the SICA's insulin response to 
k i W ~ u l a r  Clonin&':A Laboratory Manual, Cold Springs the elevated glucose was quicker and appeared to be pro- 
Harbor, New York, 1989 
Delivery of Gene ProductsiTherapeutics (Compound) 
The compound of the present invention is administered Example 2 
and dosed in accordance with good medical practice, taking Formation of Sertoli-neuron Aggregated Cells(SNACs) by 
into account the clinical condition of the individual patient, Simulated Microgravity Coculture of Sertoli Cells and Imor- 
the site and method of administration, scheduling of 30 talized NT2 Cells 
administration, patient age, sex, body weight and other Sertoli cells also have been utilized to facilitate the 
factors known to medical practitioners. The pharmaceuti- transplantation of dopaminergic cells into the brain as a 
cally "effective amount" for purposes herein is thus deter- treatment protocol for Parkinson's since Sertoli cells appear 
mined by such considerations as are known in the art. The to provide localized immunoprotection at the graft site and 
amount must be effective to achieve improvement including 35 to stimulate nerve cell viability: (Sanberg, P. R., C. V. 
but not limited to improved survival rate or more rapid Borlongan, A. I. Othberg, S. Saporta, T. B. Freeman and D. 
recovery, or improvement or elimination of symptoms and F. Cameron. Testis-derived Sertoli cells have a trophic effect 
other indicators as are selected as appropriate measures by on dopamine neurons and alleviate hemiparkinsonism in 
those skilled in the art. rats. Mature medicine, 3(10): 1129-1132.). To enhance this 
The biochambers of the instant invention can be admin- 40 transplantation treatment protocol, as was utilized in the 
istered in various ways. These include subcutaneously or diabetes transplantation (see Example 1). Sertoli cells and 
parental ly ,  including intravenous,  intraar ter ia l ,  the immortalized NT2 cell line were cocultured in simulated 
intramuscular, intraperitoneal and intranasal administration. MICROGRAVITY using the NASA high aspect rotation 
Pharmaceutically acceptable carriers, diluents, adjuvants velocity (HARV) bioreactor. Sertoli cells were isolated from 
and vehicles are also useful for administration of the bio- 45 peripuberital rats and placed immediately in HARVs along 
chambers. These refer to any diluent, carrier, adjuvant or with the NT2 cells. Maintenance medium was DMEMF12 
vehicle as commonly, known to one of ordinary skill in the supplemented with ITS+ and retinal and 21% Matrigel 
art. (MG). Cocultures were incubated at 37" C. for one or two 
weeks in maintenance medium which was replaced when 
SO needed or every 48 hours. As with Senoli cells and islets, Example 1 
Recently, Sertoli cells have been utilized to facilitate islet cells organized to form Sertoli-neuron-aggregated cells 
transplantation on the basis that the testis-derived cells (SNACs) (FIG. 6). 
provide localized immunoprotection at the graft site and At the time of SNACs collection, cell viability was 
stimulate islet viability. The relationship between Sertoli determined by trypan blue exclusion SNACs were processed 
cells and 0-cells is not yet well defined in vivo nor in vitro. 5s for morphological analysis with 3% gluteraldehyde and 
To further evaluated this relationship and to promote Sertoli/ processed into Epon/Araldite or fixed with 4% paraformal- 
islet cell 3-dimensional aggregation (SICA) in vitro, Sertoli dehyde and processed into OCT for cryosectioning. Cryo- 
cells and islets were co-cultured in simulated microgravity sections were immunostained for FasL (Sertoli cell marker), 
using the NASA high aspect rotation velocity (HARV) NuMa (NT2 cell marker) and tyrosine hydroxylase (TH- 
bioreactor. 
Sertoli cells, harvested from mammals by methods as Following the incubation period, cell viability was high 
known by those of skill in the art, and islets, obtained by (>90%) and there was segregation of Sertoli cells 
methods known to those of skill in the art as in Korbutt et (peripherally distributed) and NT2 cells (centrally 
al, were isolated from neonatal pigs by routine enzymatic distributed) when, incubated with MG. Positive FasL immu- 
digestion. Sertoli cells were. placed immediately into 65 nostaining was localized peripherally consistent with Sertoli 
HARVs at the time of isolation. Isolated islets were pre- cell distribution whereas NuMa localization was consistent 
cultured in flasks for 14 days (to expedite the removal of with the distribution of NT2 cells. Some centrally located 
25 longed. 
60 enzyme marker for dopamine synthesis). 
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cells showed positive immunostaining for TH. It appeared 15. Warnock, et al. (1989). 
that with MG, the Sertoli biochamber tissue construct was 16. Kuhn, et al. (1985). 
achieved with these two cell types, as described for the SICA 17. Naji, et al. (1981). 
(see Example 1). It is therefore concluded that the HARV 18. Weringer, et al. (1985). 
coculture of Sertoli cells, and NT2 neurons with MG, s 19. ProwSe, et al. (1986). 
resulted in the formation of NT2-filled Sertoli biochambers 20. SelawrY (1985). 
comprised of FasL positive Sertoli cells forming the bio- 21. Selawry et al. (1987). 
chamber wall and NuMa positive NT2 cells residing within 22. Selawry, et (1986). 
the biochamber. The expression of TH suggests that some of 23. Whitmore, et (1978). 24. Head, et al. (1983). 
25. Head et al. (1983). the NT2 cells had differentiated into the dopaminergic i o  phenotype indicating the use of these SNACs transplantation 26, HedgLr, M, (1989), 
protocols for the treatment of experimental Parkinson's 27, Barker et al, (1968), 
disease. 28. Selawry, et al. (1989). 
29. Martin, D C. (1982). 
30. Cameron, et al. (1990). Example 3 
Isolated Sertoli cells from peripubertal rats and pancreatic 31. Fawcett. et al. (1973). 
islets from neonatal pigs were co-cultured by conventional 32. Born, et al. (1982). 
culture technology in the same medium described for the 33. Born, et al. (1981). 
HARV simulated microgravity coculture. Sertoli cells were 34. Williams et a1 (1978) 
pre-plated 48 hours on plastic or Matrigel substrates. Pre- 2o 35. SelawrY, et al. (1993). 
treated isolated pig islets were added to the Sertoli cell- 36. Bardin, et al. (1988). 
enriched monoculture 24 hours later. This Sertoli-Islet 37. Griswold, M. D. (1993). 
co-culture was incubated at 37" C. and within 24 hr. islets 38. SelawrY. et al. (1991). 
had attached to and integrated into the underlying Sertoli 39. DeCesarts, et al. (1992). 
cells. Within another 48-72 hrs, Sertoli cells reorganized 25 40. Cantrell, et al. (1984). 
into spherical or chord-like aggregates. This process was 41. 
enhanced for those co-cultures in which Sertoli cells had 42. Hess, A D. (1985). 
been plated on the Matrigel. Islets appeared to retain their 433 Green, et al. (1978). 
structural integrity better iin the non-Matrigel co-cultures 44. Hornan, et al. (1980). 
(FIG. 4) than in the cocultures not having a Matrigel 30 45. et a1 (1995) 
substrate (FIG. 5).  Tissue constructs of Sertoli cells and 46. Lau, et al. (1996). 
pancreatic islet cells can be created in conventional cocul- 47. Wickelgren, L. (1996). 
ture in a similar manner as that observed in simulated 48. SelawrY, et al. (1996). 
microgravity coculture 49. Sanberg, et al. (1995). 
35 50. Sanberg, et al. (1966). Throughout this application, various publications, includ- 51. Sanberg, et al. (1996). ing United States patents, are referenced by author and year 52. Borlongan, et al. (1996). and patents by number. Full citations for the publications are 53. Cameron et al. (1996). listed below. The disclosures of these publications and 54. Gondos. et al. (1993). patents in their entireties are hereby incorporated by refer- 
40 55. Skinner, et al. (1993). ence into this application in order to more fully describe the 56. Edgington, S. M. (1992). state of the art to which this invention pertains. 57. Goodwin, et al. (1993). 
The invention has been described in an illustrative 58, Goodwin, et al, (1993), 
manner, and it is to be understood that the terminogoly 59, Goodwin, et al, (1992), 
which has been used is intended to be in the nature of words 45 60, ~~~k~~ et al, (1993). 
67. Cameron et al. (1991). of description rather than of limitation. 
Obviously, many modifications and variations of the 68. Cameron, et al, (1993). 
present invention are possible in light of the above teach- 69. London, eta1 (199). 
ings. It is, therefore, to be understood that within the scope 70. Cameron et al, (1990). 
of the appended claims, the invention may be practiced 50 71. Schwarz, et al, (1992). 
otherwise than as specifically described. 72. Goodwin, et al. (1996). 
et al. (1981). 
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What is claimed is: 
1. A biochamber comprising a lumen, an outer wall 
defining said lumen, and a plurality of non-Sertoli cells 
60 contained within said lumen, wherein said outer wall com- 
prises Sertoli cells, and wherein said plurality of non-Sertoli 
cells are selected from the group consisting of neuronal 
cells, NT2 cells, pancreatic islet cells, dopaminergic cells, 
and bovine chromaffin cells. 
2. The biochamber according the claim 1, wherein junc- 
tional complexes are formed between adjacent Sertoli cells 
of said outer wall. 
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3. The biochamber according to claim 1, wherein said 
Sertoli cells are arranged as a monolayer. 
4. The biochamber according to claim 1, wherein said 
plurality of non-Sertoli cells comprises pancreatic islet cells. 
5. The biochamber according to claim 1, wherein said 
plurality of non-Sertoli cells comprises neuronal cells. 
neuronal cells are NT2 neurons. 
15. The method of claim 10, wherein the outer wall 
comprises a monolayer of Sertoli cells. 
16. Amethod of transplating cells comprising the steps of 
transplanting a biochamber into a host, wherein the bio- 
chamber comprises a lumen, an outer wall defining said 
lumen, and a plurality of non-Sertoli cells containedj within 
said lumen, wherein said outer wall comrpises Sertoli cells, 
and wherein the non-Sertoli cells are selected from the group 
consisting of neuronal cells, NT2 cells, pancreatic islet cells, 
5 
6. The biochamber according to claim 5,  wherein said 
7. The biochamber according to claim 1, wherein said 
Sertoli cells of said outer wall provide immunoprotection to 10 dopaminergic cells, and bovine chromaffin cells, 
said pluralily of non-Sertoli cells within said lumen upon 
8. The biochamber according to claim 1, wherein said 
9. A biochamber comprising a lumen, an outer wall, and 15 
17, The method according to claim 16, wherein the outer 
transplantation of said biochamber. wall comprises a monolayer of Sertoli cells. 
18, The method according to claim 16, wherein the 
biochamber is spherical in shape. non-Sertoli cells are secreting cells. 
19. The method according to claim 16, wherein junctional 
a plurality of non-Sertoli cells contained within said lumen, comp~exes are formed between adjacent Sertoli cells of said 
wherein said outer wall monolayer of Sertoli cells that define outer wall, 
said lumen, whrein said monolayer of Sertoli cells encap- 20. The method of claim 16, wherein said method further 
sulate said plurality of non-Sertoli cells, wherein junctional comprises making a biochamber prior to said transplanting, 
complexes are formed between adjacent Sertoli cells of said 20 wherein said makings comprises co-culturing the Sertoli 
outer wall, and wherein said plurality of non-Sertoli cells are cells and non-Sertoli cells in the presence of a basement 
selected from the group consisiting of neuronal cells, NT2 membrane preparation for a period of time sufficicnt for the 
cells, pancreatic islet cells, dopaminergic cells, and bovine basement membrane preparation to induce the Sertoli cells 
chromaffin cells. to form an outer wall that encapsulates the plurality of 
25 non-sertoli cells within the lumen, 
21. The method of claim 20, wherein the basement 
membrane preparation comprises MATRIGEL. 
22. The method of claim 20, wherein the co-culturing is 
carried out under microgravity conditions. 
23. The method of claim 22, wherein the basement 
membrane preparation comprises MATRIGEL. 
24. A method of making a biochamber comprising 
co-culturing Sertoli cells and non-Sertoli cells under micro- 
gravity conditions for a period of time sufficient for the 
35 Sertoli cells to form an outer wall that encapsulates a 
plurality of the non-Sertoli cells, wherein said co-culturing 
is carried out in culture medium containing a basement 
membrane preparation, and wherein the non-Sertoli cells are 
selected from the group consisting of neuronal cells, NT2 
40 cells, pancreatic islet cells, dopaminergic cells, and bovine 
chromaffin cells. 
25. The method of claim 24, wherein the basement 
membrane preparation comprises MATRIGEL. 
10. A method of making a biochamber comprising: 
co-culturing Sertoli cells and non-Sertoli cells in the 
presence of a basement membrane preparation for a 
period of time sufficient for the Sertoli cells to form an 
outer wall that encapsulates a plurality of the non- 
Sertoli cells, wherein the non-Sertoli cells are selected 30 
from the group consisting of neuronal cells, NT2 cells, 
pancreatic islet cells, dopaminergic cells and bovine 
chromaffin cells. 
11. The method accordinig to claim 10, wherein said 
co-culturing is carricd out under microgravity conditions. 
12. The method according to claim 10, wherein the 
basement membrane preparation causes epithelization and 
polarization of the Sertoli cells, thereby inducing the Sertoli 
cells to form the outer wall that encapsulates the plurality of 
non-Sertoli cells. 
13. The method according to claim 10, wherein the 
basement membrane preparation comprises MATRIGEL. 
14. The method according to claim 10, wherein junctional 
complexes are formed between, adjacent Sertoli cells of said 
outer wall. * * * * *  
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